cefepime Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
antibiotics, cefalosporanic acid derivatives 535 88040-23-7

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • cefepime dihydrochloride hydrate
  • cefepime
  • cefepime hydrochloride
  • cefimen
  • tsefepim
  • cefepime HCl
A fourth-generation cephalosporin antibacterial agent that is used in the treatment of infections, including those of the abdomen, urinary tract, respiratory tract, and skin. It is effective against PSEUDOMONAS AERUGINOSA and may also be used in the empiric treatment of FEBRILE NEUTROPENIA.
  • Molecular weight: 480.56
  • Formula: C19H24N6O5S2
  • CLOGP: -5.97
  • LIPINSKI: 1
  • HAC: 11
  • HDO: 2
  • TPSA: 150.04
  • ALOGS: -4.49
  • ROTB: 7

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
4 g P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 85 % Benet LZ, Broccatelli F, Oprea TI
BA (Bioavailability) 99 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.28 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 2.20 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.78 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1.90 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Jan. 18, 1996 FDA HOSPIRA INC

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 366.05 17.98 263 12987 94364 46578448
Encephalopathy 273.66 17.98 150 13100 33439 46639373
Acute kidney injury 259.60 17.98 326 12924 235529 46437283
Status epilepticus 158.51 17.98 78 13172 13901 46658911
Sepsis 147.49 17.98 187 13063 135827 46536985
Neurotoxicity 145.06 17.98 73 13177 13644 46659168
Pyrexia 138.82 17.98 305 12945 348497 46324315
Drug reaction with eosinophilia and systemic symptoms 120.48 17.98 85 13165 29463 46643349
Cytokine release syndrome 105.79 17.98 46 13204 6177 46666635
Tubulointerstitial nephritis 101.26 17.98 59 13191 14729 46658083
Myoclonus 97.58 17.98 57 13193 14295 46658517
Septic shock 88.36 17.98 95 13155 57798 46615014
Thrombocytopenia 80.02 17.98 135 13115 126446 46546366
Mental status changes 77.39 17.98 73 13177 38015 46634797
Pneumonia 71.94 17.98 252 12998 376068 46296744
Respiratory failure 69.24 17.98 108 13142 94708 46578104
Multiple organ dysfunction syndrome 67.13 17.98 78 13172 51632 46621180
Pain 63.68 17.98 28 13222 476920 46195892
Arthralgia 57.90 17.98 16 13234 364587 46308225
Pathogen resistance 57.52 17.98 30 13220 6030 46666782
Neutrophil count decreased 57.19 17.98 66 13184 43360 46629452
Renal tubular necrosis 55.92 17.98 36 13214 10723 46662089
Klebsiella infection 54.85 17.98 30 13220 6632 46666180
Fatigue 53.06 17.98 57 13193 608640 46064172
Clostridium difficile colitis 52.62 17.98 43 13207 18510 46654302
Platelet count decreased 50.76 17.98 97 13153 99927 46572885
Rheumatoid arthritis 50.26 17.98 5 13245 240210 46432602
Cytomegalovirus test positive 48.43 17.98 21 13229 2799 46670013
Neutropenia 46.52 17.98 116 13134 143088 46529724
Hypoxia 46.38 17.98 65 13185 51773 46621039
Toxic encephalopathy 45.03 17.98 24 13226 5038 46667774
Drug resistance 44.58 17.98 38 13212 17330 46655482
Bacteraemia 42.62 17.98 34 13216 14145 46658667
Confusional state 41.31 17.98 119 13131 159773 46513039
Dizziness 40.81 17.98 23 13227 340391 46332421
Nephropathy toxic 38.88 17.98 25 13225 7429 46665383
Renal impairment 38.79 17.98 73 13177 74299 46598513
Pancytopenia 37.73 17.98 78 13172 84980 46587832
Malaise 37.43 17.98 24 13226 331208 46341604
Headache 36.10 17.98 50 13200 478302 46194510
Trichosporon infection 34.70 17.98 9 13241 240 46672572
Clostridium difficile infection 34.46 17.98 39 13211 25064 46647748
Product dose omission issue 33.98 17.98 4 13246 168516 46504296
Nephritis allergic 33.08 17.98 8 13242 159 46672653
Metabolic encephalopathy 32.91 17.98 20 13230 5383 46667429
Alopecia 32.38 17.98 4 13246 162410 46510402
Toxic epidermal necrolysis 31.25 17.98 35 13215 22243 46650569
Cytomegalovirus viraemia 30.99 17.98 18 13232 4460 46668352
Enterococcal bacteraemia 30.81 17.98 12 13238 1217 46671595
Enterococcal infection 30.56 17.98 21 13229 6966 46665846
Differentiation syndrome 30.52 17.98 11 13239 900 46671912
Nasopharyngitis 30.20 17.98 4 13246 153994 46518818
Aspartate aminotransferase increased 30.12 17.98 68 13182 78632 46594180
Abdominal discomfort 29.47 17.98 4 13246 151161 46521651
Blood creatinine increased 29.22 17.98 66 13184 76337 46596475
Acute generalised exanthematous pustulosis 29.22 17.98 23 13227 9382 46663430
Anaemia 28.81 17.98 146 13104 255633 46417179
Respiratory distress 28.50 17.98 40 13210 31876 46640936
Hypertensive heart disease 28.06 17.98 14 13236 2564 46670248
Dysbiosis 27.78 17.98 9 13241 533 46672279
Cholestatic liver injury 27.73 17.98 13 13237 2077 46670735
Toxic skin eruption 27.58 17.98 25 13225 12362 46660450
White blood cell count decreased 27.49 17.98 82 13168 112149 46560663
Bronchopulmonary aspergillosis 26.96 17.98 20 13230 7476 46665336
Graft versus host disease 26.94 17.98 19 13231 6569 46666243
Hypotension 26.35 17.98 133 13117 232456 46440356
Immune effector cell-associated neurotoxicity syndrome 25.60 17.98 9 13241 685 46672127
Renal failure 25.03 17.98 80 13170 113514 46559298
Acute respiratory distress syndrome 25.03 17.98 31 13219 21891 46650921
Hyperoxaluria 24.77 17.98 6 13244 120 46672692
Agranulocytosis 24.73 17.98 31 13219 22154 46650658
Klebsiella bacteraemia 24.34 17.98 10 13240 1166 46671646
Aphasia 24.32 17.98 35 13215 28532 46644280
Weight decreased 24.16 17.98 15 13235 210834 46461978
Drug intolerance 24.15 17.98 6 13244 147043 46525769
Gait disturbance 23.71 17.98 6 13244 145257 46527555
Acute graft versus host disease in skin 23.37 17.98 13 13237 2969 46669843
Hyperbilirubinaemia 23.10 17.98 21 13229 10417 46662395
Engraft failure 22.50 17.98 7 13243 363 46672449
Chemotherapeutic drug level increased 22.49 17.98 6 13244 179 46672633
Acute respiratory failure 22.36 17.98 34 13216 29104 46643708
Respiratory alkalosis 22.25 17.98 12 13238 2579 46670233
Fungaemia 22.23 17.98 11 13239 1980 46670832
Hepatic function abnormal 22.07 17.98 37 13213 34384 46638428
Disseminated intravascular coagulation 21.90 17.98 27 13223 18978 46653834
Rash pustular 21.64 17.98 17 13233 6912 46665900
Peripheral swelling 21.45 17.98 9 13241 158062 46514750
Osteomyelitis 21.41 17.98 29 13221 22354 46650458
Fall 21.34 17.98 38 13212 329059 46343753
Antibiotic level above therapeutic 20.94 17.98 6 13244 234 46672578
Electroencephalogram abnormal 20.59 17.98 13 13237 3741 46669071
Muscle spasms 20.25 17.98 5 13245 123108 46549704
Encephalitis Japanese B 20.24 17.98 4 13246 29 46672783
Alanine aminotransferase increased 20.13 17.98 63 13187 88388 46584424
Cholestasis 20.10 17.98 31 13219 26862 46645950
Sinusitis 19.98 17.98 6 13244 129762 46543050
Enterococcal sepsis 19.86 17.98 9 13241 1331 46671481
Staphylococcal infection 19.75 17.98 36 13214 35735 46637077
Depression 19.62 17.98 12 13238 170092 46502720
Laryngeal inflammation 19.43 17.98 5 13245 129 46672683
Rash maculo-papular 19.27 17.98 31 13219 27843 46644969
Bone marrow failure 19.16 17.98 32 13218 29637 46643175
Thrombotic microangiopathy 18.95 17.98 17 13233 8289 46664523
Leukocytosis 18.95 17.98 28 13222 23370 46649442
Electrocardiogram T wave alternans 18.91 17.98 4 13246 42 46672770
Mucosal inflammation 18.76 17.98 37 13213 38939 46633873
Lymphatic disorder 18.76 17.98 6 13244 341 46672471
Tonsillitis bacterial 18.71 17.98 5 13245 150 46672662
Drug-induced liver injury 18.62 17.98 29 13221 25339 46647473
Tinea versicolour 18.58 17.98 4 13246 46 46672766
Pseudomonas infection 18.47 17.98 18 13232 9740 46663072
Factor V inhibition 18.34 17.98 5 13245 162 46672650
Neutropenic colitis 18.23 17.98 10 13240 2222 46670590
Serotonin syndrome 18.22 17.98 28 13222 24192 46648620
Subdiaphragmatic abscess 17.99 17.98 4 13246 54 46672758

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Febrile neutropenia 253.32 15.70 312 17277 106381 29828508
Encephalopathy 209.77 15.70 164 17425 32041 29902848
Acute kidney injury 154.84 15.70 429 17160 273413 29661476
Neurotoxicity 143.67 15.70 92 17497 13090 29921799
Cytokine release syndrome 138.10 15.70 81 17508 9852 29925037
Septic shock 107.64 15.70 158 17431 63449 29871440
Multiple organ dysfunction syndrome 90.93 15.70 146 17443 63341 29871548
Pyrexia 90.16 15.70 376 17213 294113 29640776
Respiratory failure 89.13 15.70 188 17401 100454 29834435
Acute generalised exanthematous pustulosis 80.23 15.70 48 17541 6050 29928839
Sepsis 73.21 15.70 220 17369 146175 29788714
Myoclonus 72.23 15.70 61 17528 13251 29921638
Renal tubular necrosis 67.00 15.70 62 17527 15189 29919700
Fatigue 62.49 15.70 58 17531 320615 29614274
Tubulointerstitial nephritis 60.43 15.70 63 17526 17828 29917061
Hypoxia 60.36 15.70 104 17485 47750 29887139
Neutrophil count decreased 58.51 15.70 96 17493 42358 29892531
Enterococcal infection 55.89 15.70 43 17546 8181 29926708
Mental status changes 55.41 15.70 87 17502 36992 29897897
Neutropenia 54.88 15.70 183 17406 128357 29806532
Clostridium difficile colitis 52.42 15.70 50 17539 12718 29922171
Pathogen resistance 50.75 15.70 41 17548 8369 29926520
Dizziness 50.15 15.70 26 17563 194883 29740006
Status epilepticus 46.68 15.70 44 17545 11028 29923861
Drug reaction with eosinophilia and systemic symptoms 45.58 15.70 69 17520 28419 29906470
Meningitis candida 43.53 15.70 10 17579 71 29934818
Brain herniation 42.96 15.70 27 17562 3713 29931176
Product dose omission issue 42.22 15.70 3 17586 91628 29843261
Myocardial infarction 41.95 15.70 11 17578 125614 29809275
Disseminated intravascular coagulation 41.73 15.70 58 17531 22113 29912776
Death 41.54 15.70 93 17496 357190 29577699
Haemodialysis 41.03 15.70 41 17548 11032 29923857
Bacteraemia 37.53 15.70 46 17543 15514 29919375
Platelet count decreased 37.44 15.70 142 17447 105987 29828902
Pseudomonas infection 37.35 15.70 38 17551 10444 29924445
Methaemoglobinaemia 36.27 15.70 21 17568 2489 29932400
Glomerulosclerosis 36.16 15.70 14 17575 668 29934221
Botulism 34.08 15.70 10 17579 200 29934689
Immune effector cell-associated neurotoxicity syndrome 33.08 15.70 14 17575 842 29934047
Aspergillus infection 32.76 15.70 35 17554 10179 29924710
White blood cell count decreased 31.83 15.70 115 17474 83832 29851057
Fall 31.80 15.70 36 17553 181836 29753053
Enterocolitis 30.95 15.70 28 17561 6659 29928230
Cytomegalovirus enterocolitis 30.03 15.70 13 17576 827 29934062
Blood culture positive 29.72 15.70 24 17565 4895 29929994
Arthralgia 29.51 15.70 22 17567 135769 29799120
Systemic candida 29.37 15.70 19 17570 2745 29932144
Pneumonia 28.78 15.70 311 17278 333995 29600894
Depression 28.19 15.70 9 17580 90428 29844461
Metabolic encephalopathy 28.15 15.70 21 17568 3814 29931075
Eosinophilia 27.70 15.70 48 17541 22112 29912777
Bronchopulmonary aspergillosis 27.51 15.70 35 17554 12249 29922640
Thrombocytopenia 27.23 15.70 155 17434 136889 29798000
Pain 27.20 15.70 37 17552 172604 29762285
Uraemic encephalopathy 27.16 15.70 9 17580 272 29934617
Toxic encephalopathy 26.82 15.70 22 17567 4587 29930302
Nephropathy toxic 26.54 15.70 32 17557 10607 29924282
Pleural effusion 26.01 15.70 99 17490 73967 29860922
Aspartate aminotransferase increased 25.85 15.70 89 17500 63333 29871556
Antibiotic level above therapeutic 24.89 15.70 8 17581 219 29934670
Fungal infection 24.72 15.70 35 17554 13565 29921324
Transaminases increased 24.49 15.70 47 17542 23410 29911479
Drug resistance 24.37 15.70 43 17546 20090 29914799
Candida infection 24.26 15.70 37 17552 15325 29919564
Malaise 24.13 15.70 38 17551 166924 29767965
Cytokine storm 24.07 15.70 10 17579 574 29934315
Red man syndrome 23.75 15.70 11 17578 821 29934068
Clostridium difficile infection 23.51 15.70 37 17552 15746 29919143
Confusional state 23.26 15.70 147 17442 134687 29800202
Acute respiratory distress syndrome 23.25 15.70 46 17543 23426 29911463
Insomnia 23.15 15.70 13 17576 93323 29841566
Anxiety 23.05 15.70 12 17577 89859 29845030
Cytomegalovirus viraemia 22.69 15.70 22 17567 5707 29929182
Acute myeloid leukaemia recurrent 22.47 15.70 13 17576 1539 29933350
Choluria 22.46 15.70 7 17582 173 29934716
Gait disturbance 22.33 15.70 8 17581 74769 29860120
Mucormycosis 22.32 15.70 21 17568 5247 29929642
Dyspnoea 21.97 15.70 111 17478 333184 29601705
Flavobacterium infection 21.88 15.70 6 17583 93 29934796
Headache 21.47 15.70 47 17542 182259 29752630
Pneumonia bacterial 21.39 15.70 27 17562 9376 29925513
Kidney fibrosis 21.34 15.70 14 17575 2071 29932818
Myelodysplastic syndrome 21.32 15.70 39 17550 18739 29916150
Toxic epidermal necrolysis 21.31 15.70 38 17551 17902 29916987
Peripheral swelling 21.04 15.70 5 17584 61069 29873820
Blood pressure increased 20.96 15.70 8 17581 71920 29862969
Immune thrombocytopenia 20.87 15.70 24 17565 7567 29927322
Procalcitonin increased 20.67 15.70 11 17578 1107 29933782
Septic embolus 20.51 15.70 11 17578 1124 29933765
Aphasia 20.35 15.70 39 17550 19400 29915489
Alanine aminotransferase increased 20.35 15.70 92 17497 74184 29860705
Hypersensitivity vasculitis 20.06 15.70 17 17572 3706 29931183
Asthenia 20.04 15.70 65 17524 221225 29713664
Blood creatinine increased 19.90 15.70 106 17483 91269 29843620
Trichosporon infection 19.79 15.70 9 17580 644 29934245
Respiratory distress 19.76 15.70 53 17536 32919 29901970
Staphylococcal sepsis 19.63 15.70 26 17563 9465 29925424
Bacterial toxaemia 19.62 15.70 6 17583 139 29934750
Aeromonas infection 19.26 15.70 7 17582 280 29934609
Blastomycosis 19.09 15.70 7 17582 287 29934602
Renal failure 18.87 15.70 135 17454 128831 29806058
Feeling abnormal 18.87 15.70 5 17584 56751 29878138
Pancytopenia 18.75 15.70 99 17490 84953 29849936
Cerebral aspergillosis 18.67 15.70 11 17578 1347 29933542
Pulmonary haemorrhage 18.31 15.70 25 17564 9367 29925522
Eye infection fungal 18.30 15.70 7 17582 323 29934566
Acute lymphocytic leukaemia recurrent 18.24 15.70 14 17575 2653 29932236
Hypercapnia 17.67 15.70 16 17573 3808 29931081
Retinal ischaemia 17.49 15.70 7 17582 365 29934524
Intracranial mass 17.38 15.70 10 17579 1171 29933718
Drug intolerance 17.07 15.70 3 17586 45288 29889601
Drug level increased 17.02 15.70 35 17554 18319 29916570
Cholestatic liver injury 17.00 15.70 11 17578 1590 29933299
Dysbiosis 16.93 15.70 7 17582 397 29934492
Cholestasis 16.90 15.70 42 17547 24908 29909981
Weight decreased 16.87 15.70 40 17549 150881 29784008
Rash morbilliform 16.82 15.70 13 17576 2489 29932400
Hospitalisation 16.56 15.70 3 17586 44316 29890573
Vanishing bile duct syndrome 16.52 15.70 8 17581 660 29934229
Nasopharyngitis 16.40 15.70 7 17582 58842 29876047
Unresponsive to stimuli 16.37 15.70 43 17546 26376 29908513
Adenoviral haemorrhagic cystitis 16.35 15.70 7 17582 433 29934456
Necrotising retinitis 15.89 15.70 8 17581 717 29934172

Pharmacologic Action:

SourceCodeDescription
ATC J01DE01 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
OTHER BETA-LACTAM ANTIBACTERIALS
Fourth-generation cephalosporins
ATC J01RA06 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
COMBINATIONS OF ANTIBACTERIALS
Combinations of antibacterials
FDA CS M0003827 Cephalosporins
FDA EPC N0000175488 Cephalosporin Antibacterial
MeSH PA D000900 Anti-Bacterial Agents
MeSH PA D000890 Anti-Infective Agents
CHEBI has role CHEBI:36047 antibacterial drugs

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Infection due to Pseudomonas aeruginosa indication 11218009
Pneumonia due to Streptococcus indication 34020007
Pneumonia due to Pseudomonas indication 41381004
Bacterial pneumonia indication 53084003 DOID:874
Klebsiella cystitis indication 60867007
Infectious disease of abdomen indication 128070006
Bacterial infection due to Klebsiella pneumoniae indication 186435004
Bacterial peritonitis indication 197171003
Pneumococcal pneumonia indication 233607000
Escherichia coli urinary tract infection indication 301011002
Proteus urinary tract infection indication 301012009
Streptococcus pyogenes infection indication 302809008
Bacterial urinary infection indication 312124009
Infection due to Staphylococcus aureus indication 406602003
Urinary tract infection caused by Klebsiella indication 369001000119100
Complicated Proteus UTI indication
E. Coli Pyelonephritis indication
Complicated Urinary Tract Infections indication
Complicated Bacteroides Peritonitis indication
Complicated Streptococcus Peritonitis indication
Klebsiella Pyelonephritis indication
Complicated E. Coli Peritonitis indication
Enterobacter Pneumonia indication
Complicated Klebsiella Peritonitis indication
Proteus Pyelonephritis indication
Myoclonus contraindication 17450006
Colitis contraindication 64226004 DOID:0060180
Blood coagulation disorder contraindication 64779008 DOID:1247
Factor II deficiency contraindication 73975000
Disorder of brain contraindication 81308009 DOID:936
Seizure disorder contraindication 128613002
Impaired renal function disorder contraindication 197663003
Pseudomembranous enterocolitis contraindication 397683000

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.32 acidic
pKa2 13.31 acidic
pKa3 3.1 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Bacterial penicillin-binding protein Enzyme INHIBITOR CHEMBL CHEMBL

External reference:

IDSource
4024049 VUID
N0000022054 NUI
D01157 KEGG_DRUG
123171-59-5 SECONDARY_CAS_RN
4020908 VANDF
4024049 VANDF
C0055003 UMLSCUI
CHEBI:478164 CHEBI
9WT PDB_CHEM_ID
CHEMBL186 ChEMBL_ID
CHEMBL1200962 ChEMBL_ID
DB01413 DRUGBANK_ID
D000077723 MESH_DESCRIPTOR_UI
6092 INN_ID
2622 PUBCHEM_CID
10772 IUPHAR_LIGAND_ID
807PW4VQE3 UNII
20481 RXNORM
116681 MMSL
4373 MMSL
d03882 MMSL
004974 NDDF
004975 NDDF
370370003 SNOMEDCT_US
370371004 SNOMEDCT_US
96048006 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
CEFEPIME HYDROCHLORIDE AND DEXTROSE HUMAN PRESCRIPTION DRUG LABEL 1 0264-3193 INJECTION, SOLUTION 1 g INTRAVENOUS NDA 29 sections
CEFEPIME HYDROCHLORIDE AND DEXTROSE HUMAN PRESCRIPTION DRUG LABEL 1 0264-3195 INJECTION, SOLUTION 2 g INTRAVENOUS NDA 29 sections
Cefepime HUMAN PRESCRIPTION DRUG LABEL 1 0338-1301 INJECTION, SOLUTION 1 g INTRAVENOUS NDA 28 sections
Cefepime HUMAN PRESCRIPTION DRUG LABEL 1 0409-9566 INJECTION, POWDER, FOR SOLUTION 1 g INTRAVENOUS ANDA 27 sections
Cefepime HUMAN PRESCRIPTION DRUG LABEL 1 0409-9735 INJECTION, POWDER, FOR SOLUTION 2 g INTRAVENOUS ANDA 27 sections
Cefepime Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0781-3222 INJECTION, POWDER, FOR SOLUTION 1 g INTRAVENOUS ANDA 27 sections
Cefepime Hydrochloride HUMAN PRESCRIPTION DRUG LABEL 1 0781-3223 INJECTION, POWDER, FOR SOLUTION 2 g INTRAVENOUS ANDA 27 sections
cefepime HUMAN PRESCRIPTION DRUG LABEL 1 25021-121 INJECTION, POWDER, FOR SOLUTION 1 g INTRAVENOUS ANDA 30 sections
cefepime HUMAN PRESCRIPTION DRUG LABEL 1 25021-121 INJECTION, POWDER, FOR SOLUTION 1 g INTRAVENOUS ANDA 30 sections
cefepime HUMAN PRESCRIPTION DRUG LABEL 1 25021-122 INJECTION, POWDER, FOR SOLUTION 2 g INTRAVENOUS ANDA 30 sections
cefepime HUMAN PRESCRIPTION DRUG LABEL 1 25021-122 INJECTION, POWDER, FOR SOLUTION 2 g INTRAVENOUS ANDA 30 sections
Cefepime HUMAN PRESCRIPTION DRUG LABEL 1 44567-130 INJECTION, POWDER, FOR SOLUTION 1 g INTRAVENOUS ANDA 27 sections
Cefepime HUMAN PRESCRIPTION DRUG LABEL 1 44567-131 INJECTION, POWDER, FOR SOLUTION 2 g INTRAVENOUS ANDA 27 sections
Cefepime HUMAN PRESCRIPTION DRUG LABEL 1 44567-240 INJECTION, POWDER, FOR SOLUTION 1 g INTRAVENOUS ANDA 27 sections
Cefepime HUMAN PRESCRIPTION DRUG LABEL 1 44567-241 INJECTION, POWDER, FOR SOLUTION 2 g INTRAVENOUS ANDA 27 sections
Cefepime HUMAN PRESCRIPTION DRUG LABEL 1 60505-6144 INJECTION, POWDER, FOR SOLUTION 1 g INTRAVENOUS ANDA 28 sections
Cefepime HUMAN PRESCRIPTION DRUG LABEL 1 60505-6145 INJECTION, POWDER, FOR SOLUTION 2 g INTRAVENOUS ANDA 28 sections
Cefepime HUMAN PRESCRIPTION DRUG LABEL 1 60505-6146 INJECTION, POWDER, FOR SOLUTION 1 g INTRAVENOUS ANDA 28 sections
Cefepime HUMAN PRESCRIPTION DRUG LABEL 1 60505-6147 INJECTION, POWDER, FOR SOLUTION 2 g INTRAVENOUS ANDA 28 sections
Cefepime HUMAN PRESCRIPTION DRUG LABEL 1 63323-326 INJECTION, POWDER, FOR SOLUTION 1 g INTRAVENOUS ANDA 27 sections
Cefepime HUMAN PRESCRIPTION DRUG LABEL 1 63323-340 INJECTION, POWDER, FOR SOLUTION 2 g INTRAVENOUS ANDA 27 sections
CEFEPIME HUMAN PRESCRIPTION DRUG LABEL 1 66288-8100 INJECTION, POWDER, FOR SOLUTION 100 g INTRAVENOUS ANDA 18 sections
Cefepime HUMAN PRESCRIPTION DRUG LABEL 1 66794-209 INJECTION, POWDER, FOR SOLUTION 1 g INTRAMUSCULAR ANDA 17 sections
Cefepime HUMAN PRESCRIPTION DRUG LABEL 1 66794-210 INJECTION, POWDER, FOR SOLUTION 2 g INTRAMUSCULAR ANDA 17 sections
Cefepime HUMAN PRESCRIPTION DRUG LABEL 1 67184-1002 INJECTION, POWDER, FOR SOLUTION 500 mg INTRAVENOUS ANDA 28 sections
Cefepime HUMAN PRESCRIPTION DRUG LABEL 1 67184-1003 INJECTION, POWDER, FOR SOLUTION 1 g INTRAVENOUS ANDA 28 sections
Cefepime HUMAN PRESCRIPTION DRUG LABEL 1 67184-1004 INJECTION, POWDER, FOR SOLUTION 2 g INTRAVENOUS ANDA 28 sections
Cefepime HUMAN PRESCRIPTION DRUG LABEL 1 71288-008 INJECTION, POWDER, FOR SOLUTION 1 g INTRAVENOUS ANDA 30 sections
Cefepime HUMAN PRESCRIPTION DRUG LABEL 1 71288-009 INJECTION, POWDER, FOR SOLUTION 2 g INTRAVENOUS ANDA 30 sections
Cefepime HUMAN PRESCRIPTION DRUG LABEL 1 71288-020 INJECTION, POWDER, FOR SOLUTION 1 g INTRAVENOUS ANDA 30 sections